Autosomal Dominant Tubulointerstitial Kidney Disease (ADTKD)

Autosomal dominant medullary cystic kidney disease is a lifelong, inherited kidney condition. “Autosomal dominant” means a parent with the disease has a 50% chance of passing it to each child. The disease mainly injures the long tubes in the kidney (tubules) and the surrounding support tissue (interstitium). Over time, these injuries cause scarring (fibrosis). The kidneys shrink and do not filter the blood well. Urine tests often look almost normal because the main problem is not in the glomeruli (the kidney’s filters) but in the tubules. Many people first notice features like high uric acid and gout (especially with UMOD gene changes), slow but steady fall in kidney function, and, in some subtypes, mild anemia and high potassium in childhood (especially with REN gene changes). Small cysts can form near the kidney’s center (medulla), but they are not always present. PMC+2NCBI+2

Autosomal dominant medullary cystic kidney disease (ADTKD) is a group of inherited kidney disorders that run in families (autosomal dominant means a 50% chance a child inherits it if one parent has it). The disease mainly damages the kidney’s tubules and surrounding tissue, causing slow loss of kidney function over many years. Most people have few symptoms at first—a “bland” urine test with little or no blood or protein is typical. Over time, chronic kidney disease (CKD) develops and may lead to kidney failure in adulthood; many patients eventually need dialysis or a kidney transplant. Several genes can cause ADTKD, including MUC1, UMOD, REN, HNF1B, and SEC61A1. There is no disease-specific curative drug yet; treatment follows standard CKD care (blood pressure control, treating complications like gout, anemia, acidosis, mineral-bone disorder) and, when needed, dialysis or transplant. Notably, ADTKD does not recur in a transplanted kidney. NCBI

Other names

• Autosomal dominant tubulointerstitial kidney disease (ADTKD) — current umbrella name. Subtype labels use the gene (e.g., ADTKD-UMOD, ADTKD-MUC1, ADTKD-REN, ADTKD-HNF1B, ADTKD-DNAJB11, ADTKD-APOA4 in rare reports). PMC+1

• Medullary cystic kidney disease (MCKD) — older term: MCKD type 2 ≈ UMOD; MCKD type 1 ≈ MUC1. PubMed

• Familial juvenile hyperuricemic nephropathy (FJHN) or uromodulin-associated kidney disease (UAKD) — older names, mainly for UMOD-related disease. PubMed

Types

1. ADTKD-UMOD (uromodulin gene)
   Most common subtype. Often shows high uric acid and early gout (teens–30s), mild or absent urinary abnormalities, and steady CKD progression to kidney failure in mid-to-late adulthood. Pathology shows tubulointerstitial fibrosis; uromodulin misfolding stresses tubular cells. PMC+1

2. ADTKD-MUC1 (mucin-1 gene)
   May show only CKD with bland urine; gout is less typical. Genetic testing is specialized because the causal “frameshift” variant lies in a hard-to-sequence repeat region. Inheritance is autosomal dominant (50% risk to children). NCBI

3. ADTKD-REN (renin gene)
   Often presents in childhood with mild low blood pressure, high potassium, mild metabolic acidosis, mild anemia, sometimes low sodium, and CKD. Hyperuricemia can occur but gout is less prominent than in UMOD. PubMed+1

4. ADTKD-HNF1B
   Broader syndrome (renal cysts, diabetes of young, genital tract malformations, elevated liver enzymes, hypomagnesemia). Kidney disease is tubulointerstitial and cystic. PubMed

5. Other rare/emerging genes (DNAJB11, APOA4)
   Reported in a small number of families; recognition is increasing with genetic testing. AJKD

Note on frequency: Recent studies suggest UMOD and MUC1 together account for most ADTKD families; estimates vary by cohort, with UMOD slightly more frequent in some series. Kireports+1

Causes

Important: ADTKD is a genetic disease. “Causes” here describe the underlying gene problems and factors that speed kidney damage. Each short paragraph explains what and why.

1. UMOD pathogenic variants
   Changes in the uromodulin gene make the protein misfold and build up inside thick ascending limb cells. This stresses and injures them, leading to scarring and gradual loss of kidney function; uric acid handling is impaired → hyperuricemia/gout. PMC+1

2. MUC1 frameshift variants
   An abnormal fragment of mucin-1 accumulates in tubular cells and is toxic, causing interstitial scarring and CKD with a bland urinalysis. NCBI

3. REN (renin) variants
   Abnormal renin affects the juxtaglomerular apparatus and salt balance, producing low renin, low blood pressure, hyperkalemia, acidosis, anemia, and CKD beginning in childhood. PubMed

4. HNF1B variants
   This transcription factor controls many kidney development genes; variants lead to tubulointerstitial disease plus cysts and multi-system features. PubMed

5. DNAJB11 variants
   Protein-folding chaperone defects lead to atypical cystic/tubulointerstitial disease with progressive CKD. (Rare, but recognized.) PMC

6. APOA4 variants (rare)
   Reported in a few families; mechanism likely relates to tubular stress and interstitial scarring. AJKD

7. Autosomal dominant inheritance
   Passing one faulty copy from an affected parent is enough to cause disease; each child has a 50% chance. This inheritance pattern explains vertical transmission across generations. NCBI

8. Protein misfolding stress
   In multiple subtypes (UMOD, MUC1), misfolded proteins stress tubular cell machinery (ER stress), triggering inflammation and fibrosis over years. PMC

9. Interstitial fibrosis
   Chronic injury turns into scarring that squeezes vessels and tubules, reducing oxygen delivery and function → CKD progression. (Core pathology of ADTKD.) PMC

10. Impaired uric acid transport
    UMOD-related dysfunction reduces urate excretion → hyperuricemia and gout, a hallmark in many families. PubMed

11. Salt handling defects
    REN and other tubular gene defects disturb sodium transport, causing low or normal-low blood pressure and electrolyte issues that stress kidneys over time. PubMed

12. Early-life tubular vulnerability
    In ADTKD-REN, problems often start in childhood because renin is key to kidney blood flow and salt balance during growth. PubMed

13. Reduced nephron reserve
    Years of tubular injury silently reduce functioning nephron units, so eGFR falls slowly without heavy protein in the urine. PMC

14. Hyperuricemia-related crystal inflammation
    In UMOD disease, urate crystals can inflame joints (gout), generating systemic inflammation that may indirectly burden kidneys. PubMed

15. Secondary hits (dehydration)
    Recurrent dehydration concentrates toxins and uric acid, worsening tubular stress in already fragile tubules. (General CKD physiology; prudent avoidance recommended by CKD guidance.) KDIGO

16. Nephrotoxin exposure (e.g., NSAIDs)
    Painkillers that reduce kidney blood flow, and other nephrotoxins, can accelerate damage in vulnerable tubules. (CKD guideline principle.) KDIGO

17. Uncontrolled hypertension (if present)
    While many have normal-low BP, some develop hypertension later; poor control speeds CKD scarring. (CKD principle.) KDIGO

18. Episodes of obstruction or stones
    Occasional stones with hyperuricemia can transiently block urine flow; even short obstructions can injure tubules. (General nephrology principle; stones recognized with hyperuricemia.) Merck Manuals

19. Superimposed infections
    Acute kidney infections or severe systemic infections can further damage tubules that are already stressed. (General CKD risk.) KDIGO

20. Late presentation/under-diagnosis
    Because urinalysis may be near normal, families can go undiagnosed; late recognition delays protective care, allowing more scarring before CKD management begins. PMC

Common symptoms and signs

1. Slowly worsening tiredness
   Falling kidney function leads to toxin buildup and sometimes mild anemia (especially in ADTKD-REN), causing fatigue. PubMed

2. Gout attacks
   Sudden painful, swollen big toe or other joints due to uric acid crystals—typical in UMOD-related disease, sometimes early in life. PubMed

3. High uric acid on blood tests
   Often noticed before CKD is obvious; a clue to ADTKD-UMOD. PubMed

4. Mild or no urinary symptoms
   Urinalysis may look normal; blood or protein in urine is usually mild because damage centers on tubules, not glomeruli. PMC

5. Increased thirst or urination
   Tubular damage reduces the kidney’s ability to concentrate urine; some people notice frequent urination. Merck Manuals

6. Low or normal-low blood pressure (ADTKD-REN)
   Because renin is low; may cause lightheadedness when standing. PubMed

7. High potassium (ADTKD-REN)
   Can cause weakness or, if severe, heart rhythm changes; requires prompt care. PubMed

8. Mild metabolic acidosis (ADTKD-REN)
   Acid build-up may contribute to fatigue and bone effects. PubMed

9. Mild anemia (ADTKD-REN)
   Appears in childhood due to renin-angiotensin system effects. PubMed

10. Small kidneys on imaging (later)
    As scarring progresses, kidneys may look smaller; cysts may be present but are not required for diagnosis. PMC

11. Family history across generations
    A parent, grandparent, or multiple relatives with CKD, gout, or kidney failure points toward ADTKD. PMC

12. Nausea or appetite loss (late CKD)
    When eGFR becomes low, uremic symptoms can appear. (CKD principle.) KDIGO

13. Swelling in legs (later CKD)
    From fluid and salt imbalance as kidney function declines. (CKD principle.) KDIGO

14. Bone/mineral problems (late CKD)
    CKD-mineral bone disorder can cause bone pain, fractures, or itching. (CKD principle.) KDIGO

15. No symptoms at first
    Many people feel well for years; the condition is often found through family screening or routine blood tests. PMC

Diagnostic tests

A) Physical-exam / bedside checks

1. Blood pressure (sitting/standing)
   Looks for low BP (ADTKD-REN) or later-life hypertension; orthostatic drop suggests volume/salt issues. PubMed

2. Joint examination for gout
   Red, tender, swollen joints raise suspicion for UMOD disease when combined with CKD and family history. PubMed

3. Volume status check
   Dry mouth, low skin turgor, or edema help guide salt and fluid advice in CKD. KDIGO

4. Abdominal palpation
   Large polycystic kidneys are not typical; normal or small kidneys fit ADTKD—this contrast helps the differential. PMC

5. Family pedigree mapping
   Charting which relatives have CKD/gout clarifies autosomal dominant inheritance. PMC

B) “Manual” clinical assessments (simple tools at the visit)

6. Standard urinalysis and microscopy
   Often “bland” (little protein/hematuria); this pattern points away from primary glomerular diseases. PMC

7. Spot urine albumin-to-creatinine ratio
   Usually low or mildly elevated; helpful for CKD staging and risk. KDIGO

8. 24-hour urine (selective use)
   Assesses concentrating ability and uric acid excretion; useful in hyperuricemia/gout evaluations. PubMed

9. Diet/medication review
   Identifies nephrotoxins (e.g., NSAIDs) and high-purine or very low-fluid habits that may worsen disease course. KDIGO

10. Ambulatory/home BP monitoring
    If clinic readings are misleading, out-of-office measurements better reflect true BP burden on kidneys. (CKD guideline principle.) KDIGO

C) Laboratory & pathological tests

11. Serum creatinine and eGFR
    Key to detect and follow CKD progression over time. KDIGO

12. Serum uric acid
    Often high in ADTKD-UMOD, guiding gout management and supporting the subtype clue. PubMed

13. Electrolytes and acid-base (Na, K, HCO₃⁻)
    ADTKD-REN can show hyperkalemia and metabolic acidosis; others are usually normal until later CKD stages. PubMed

14. Hemoglobin and iron studies
    Mild anemia can appear early in ADTKD-REN and later in CKD of any cause; results guide treatment. PubMed+1

15. Genetic testing panel for ADTKD genes
    Confirms the diagnosis and subtype (UMOD, MUC1, REN, HNF1B, DNAJB11, APOA4). MUC1 testing may require specialized assays due to the hard-to-sequence repeat region. PMC+1

16. Kidney biopsy (selected cases)
    Not always needed if genetics is clear. When done, shows tubulointerstitial fibrosis with relatively mild glomerular changes; cysts may be corticomedullary. PMC

D) Electrodiagnostic tests

17. 12-lead ECG
    Assesses effects of hyperkalemia (peaked T-waves, conduction issues), especially relevant in ADTKD-REN or advanced CKD. PubMed

18. Continuous/telemetry ECG (when indicated)
    If potassium is markedly high or symptoms are concerning, monitoring detects arrhythmias promptly. (CKD safety practice.) KDIGO

(Kidney diseases rarely need nerve-conduction or brain-wave tests; here “electrodiagnostic” mainly means ECG monitoring related to electrolyte disturbances.)

E) Imaging tests

19. Renal ultrasound
    Often normal or small kidneys; medullary/corticomedullary cysts may be seen but are not required. Ultrasound also screens for obstruction or stones. PMC

20. CT/MRI (selective)
    If ultrasound is unclear or stones/other anatomy questions remain, cross-sectional imaging can help; findings are compatible with tubulointerstitial scarring and occasional cysts. PMC

Non-pharmacological treatments (therapies & other measures)

1. Genetic counseling and family testing. Explain inheritance, offer testing to at-risk relatives, and plan life choices (pregnancy, screening). Mechanism: identify the variant so family members can be tested and monitored early. NCBI+1

2. Regular CKD follow-up. Scheduled monitoring of eGFR, electrolytes, uric acid, blood pressure, and complications allows early action. Mechanism: detect change before symptoms and adjust care per KDIGO CKD 2024. KDIGO

3. Blood pressure targets. Treat hypertension to guideline targets (adults commonly <130/<80 mmHg with standardized measurement) to slow CKD decline. Mechanism: lower intraglomerular pressure and reduce scarring. KDIGO

4. Sodium restriction. Aim for <2 g sodium/day (~5 g salt). Mechanism: lowers BP and reduces fluid overload, helping kidneys work less hard. KDIGO

5. Protein moderation. Maintain ~0.8 g/kg/day in adults with CKD unless otherwise indicated; avoid very high intakes. Mechanism: reduces nitrogenous waste load while preserving nutrition. ScienceDirect

6. Dietary pattern. Emphasize vegetables, fruits (as potassium allows), whole grains, plant proteins, unsaturated fats; limit ultra-processed foods. Mechanism: improves cardiometabolic risk and CKD outcomes. KDIGO

7. Weight management and physical activity. Regular moderate exercise supports BP, glucose, and cardiovascular health. Mechanism: improves endothelial function and reduces CKD progression risk factors. KDIGO

8. Hydration guidance. Maintain steady, adequate fluid intake (unless restricted by your clinician). Mechanism: supports tubular flow and reduces crystal precipitation; individualized in CKD. KDIGO

9. Avoid nephrotoxins. Limit/avoid NSAIDs and unnecessary contrast dyes; review over-the-counter remedies and herbal products. Mechanism: prevents additional tubular injury. KDIGO

10. Vaccinations. Keep influenza and pneumococcal vaccines up to date; ensure hepatitis B immunization as CKD advances. Mechanism: prevent infections that can sharply worsen kidney function. U.S. Food and Drug Administration+2U.S. Food and Drug Administration+2

11. Anemia and bone-mineral education. Lifestyle and diet counseling (iron-rich foods, phosphorus awareness) coordinated with medical therapy. Mechanism: supports guideline-concordant ESA/iron and CKD-MBD care. KDIGO

12. Gout self-management. Elevate joint, ice during flares, and plan rapid access to flare treatment; reduce purine-dense meats and alcohol. Mechanism: lowers flare frequency and pain. MedlinePlus

13. Smoking cessation. Stopping tobacco slows CKD progression and lowers CVD risk. Mechanism: reduces oxidative and vascular injury. KDIGO

14. Medication review (“deprescribing”). Regularly check drug doses versus eGFR and interactions (e.g., with allopurinol, diuretics). Mechanism: avoid dose-related toxicity in CKD. KDIGO

15. Early access planning. As eGFR falls, plan dialysis modality and vascular/peritoneal access early (ESKD “Life-Plan”). Mechanism: avoids urgent catheters and complications. PMC

16. Transplant evaluation at the right time. Refer when eGFR approaches <20 mL/min and trajectory is downward so you can be listed. Mechanism: reduces time on dialysis and improves survival. KDIGO+1

17. Education on heat/illness precautions. Prevent dehydration and acute kidney injury during illness (sick-day rules). Mechanism: preserves residual kidney function. KDIGO

18. Sleep, stress, and mental health care. Address insomnia, depression, and stress that worsen BP and self-care. Mechanism: improves adherence and physiologic BP responses. KDIGO

19. Pregnancy counseling. Discuss risks, medication safety, and inheritance before pregnancy. Mechanism: plan safe gestation and neonatal outcomes. KDIGO

20. Patient support networks. Connect with rare-kidney communities for education and trials as they emerge. Mechanism: improves literacy and access to advances. Rare Kidney

---

Drug treatments

1) Allopurinol — xanthine oxidase inhibitor.
Purpose/mechanism: Lowers uric acid production to prevent gout flares common in UMOD-ADTKD. Dose: Often start low (e.g., 50–100 mg daily) and titrate cautiously in CKD; many labels recommend lower starts and gradual increments. Timing: Once daily. Notes: Reduce dose if eGFR is low; screen for severe cutaneous reaction risk in high-risk ancestries (e.g., HLA-B*58:01 where appropriate). Side effects: Rash (can be severe), liver enzyme elevations, cytopenias; rare hypersensitivity. Evidence source: FDA labels for allopurinol tablets and ZYLOPRIM. FDA Access Data+1

2) Febuxostat — xanthine oxidase inhibitor.
Purpose/mechanism: Alternative urate-lowering when allopurinol is not tolerated; inhibits xanthine oxidase to reduce uric acid. Dose: 40–80 mg once daily; adjust for severe renal impairment per label. Side effects: Liver enzyme elevations, rash; boxed warning for cardiovascular death risk—use only after weighing risks. Use note: Avoid starting during an acute flare; give flare prophylaxis initially. Evidence source: FDA label for ULORIC (febuxostat). FDA Access Data

3) Colchicine — anti-inflammatory for gout flares/prophylaxis.
Purpose/mechanism: Blocks microtubules to reduce neutrophil-driven inflammation in gout. Dose: Flare dosing and prophylaxis require renal-adjusted regimens; many labels caution dose reduction or avoidance with strong CYP3A4/P-gp inhibitors in CKD. Side effects: GI upset, myopathy (risk rises with statins and in CKD), cytopenias. Evidence source: FDA structured product labeling (SPL) for colchicine products. FDA Access Data

4) Prednisone (or prednisolone) — corticosteroid for acute gout when NSAIDs are unsuitable.
Purpose/mechanism: Broad anti-inflammatory effect to settle flares. Dose: Short courses (e.g., 20–40 mg/day tapered over several days) individualized by clinician. Side effects: Hyperglycemia, mood changes, fluid retention, infection risk; use the lowest effective dose for the shortest time. Evidence source: FDA prednisone/prednisolone labels (e.g., RAYOS). FDA Access Data

5) Lisinopril — ACE inhibitor.
Purpose/mechanism: Lowers BP and intraglomerular pressure to slow CKD progression; benefits extend even with modest albuminuria. Dose: Often 5–20 mg once daily (titrate to BP and tolerance). Side effects: Cough, hyperkalemia, creatinine rise, angioedema; contraindicated in pregnancy. Evidence source: FDA Zestril label. FDA Access Data

6) Losartan — ARB.
Purpose/mechanism: Alternative to ACE inhibitor; also lowers serum uric acid slightly, which helps in gout-prone patients. Dose: Typically 50–100 mg daily (adjust to BP). Side effects: Hyperkalemia, dizziness, creatinine rise; contraindicated in pregnancy. Evidence source: FDA Cozaar label. FDA Access Data

7) Furosemide — loop diuretic (for edema/hypertension in CKD).
Purpose/mechanism: Increases salt and water excretion when volume overloaded. Dose: Highly individualized; careful monitoring needed. Side effects: Dehydration, electrolyte loss, hyperuricemia (can worsen gout), ototoxicity at high doses. Evidence source: FDA furosemide labels. FDA Access Data+1

8) Dapagliflozin — SGLT2 inhibitor (renal-protective in CKD subgroups).
Purpose/mechanism: Promotes glycosuria/natriuresis, reduces intraglomerular pressure and CKD progression in many CKD phenotypes; consider even without diabetes per label indications for CKD. Dose: Usually 10 mg once daily, depending on eGFR and label. Side effects: Genital infections, volume depletion; hold during acute illness. Evidence source: FDA FARXIGA label.

9) Epoetin alfa — erythropoiesis-stimulating agent (ESA).
Purpose/mechanism: Treats symptomatic CKD anemia when iron replete; stimulates red cell production. Dose: Intermittent injections, individualized to hemoglobin targets per practice. Side effects: Hypertension, thrombosis risk if over-corrected. Evidence source: FDA EPOGEN label.

10) Darbepoetin alfa — long-acting ESA.
Purpose/mechanism: Similar to epoetin with longer dosing intervals. Dose: Weekly to every 2–4 weeks based on response. Side effects: Similar to epoetin; avoid overtreatment. Evidence source: FDA ARANESP label.

11) Iron sucrose (Venofer) — IV iron.
Purpose/mechanism: Replenishes iron stores to enable ESA response and correct iron-deficiency anemia. Dose: IV total dose over several sessions per label. Side effects: Hypotension, infusion reactions. Evidence source: FDA Venofer label. FDA Access Data

12) Ferric carboxymaltose (Injectafer) — IV iron.
Purpose/mechanism: Larger single doses to replete iron quickly. Dose: Typically 750–1000 mg per session (per label schedule). Side effects: Hypophosphatemia, hypertension, infusion reactions. Evidence source: FDA Injectafer label. FDA Access Data

13) Sevelamer carbonate — phosphate binder.
Purpose/mechanism: Binds dietary phosphate to manage CKD-MBD as GFR falls. Dose: With meals; titrate to serum phosphate. Side effects: GI upset, constipation. Evidence source: FDA Renvela label.

14) Calcium acetate — phosphate binder.
Purpose/mechanism: Reduces phosphate absorption; watch calcium load. Dose: With meals; titrate to labs. Side effects: Hypercalcemia, GI symptoms. Evidence source: FDA PhosLo documents. FDA Access Data

15) Calcitriol — active vitamin D.
Purpose/mechanism: Treats CKD hypocalcemia/secondary hyperparathyroidism by raising calcium absorption and suppressing PTH. Dose: Microgram doses orally; monitor Ca/P. Side effects: Hypercalcemia, hyperphosphatemia. Evidence source: FDA Rocaltrol label. FDA Access Data

16) Patiromer — potassium binder.
Purpose/mechanism: Treats hyperkalemia, allowing continued ACEi/ARB use. Dose: Oral powder once daily; separate from other meds. Side effects: Constipation, hypomagnesemia. Evidence source: FDA VELTASSA label.

17) Sodium zirconium cyclosilicate — potassium binder.
Purpose/mechanism: Exchanges sodium/hydrogen for potassium in the gut to correct hyperkalemia. Dose: Initial three-times-daily then maintenance. Side effects: Edema, GI symptoms. Evidence source: FDA LOKELMA label.

18) Pegloticase — refractory gout biologic.
Purpose/mechanism: IV uricase that breaks down uric acid for severe, refractory gout; useful in advanced CKD when standard agents fail. Dose: Every 2 weeks IV with monitoring. Side effects: Infusion and anaphylaxis risks; need prophylaxis. Evidence source: FDA KRYSTEXXA label.

19) Atorvastatin — statin for cardiovascular risk in CKD.
Purpose/mechanism: Lowers LDL and major vascular events; CKD carries high CVD risk. Dose: 10–80 mg daily; adjust per risk and interactions. Side effects: Myopathy (rare), liver enzyme elevations; avoid in pregnancy. Evidence source: FDA LIPITOR label. FDA Access Data

20) Doses of diuretics/alkali as adjuncts (clinician-directed).
Purpose/mechanism: Individualized diuretic strategies (e.g., furosemide) for volume and oral alkali for metabolic acidosis per CKD guidelines (specific branded alkali tablets have varied labels). Side effects: Electrolyte changes; over-alkalinization. Evidence source: CKD 2024 recommendations for acidosis and medication review. KDIGO

Important note: There are no FDA-approved drugs that “reverse” or “regenerate” kidneys in ADTKD. Medications above manage complications and slow CKD where evidence exists; definitive renal replacement is dialysis or transplant when indicated. KDIGO

---

Dietary molecular supplements

1. Vitamin D3 (cholecalciferol). Helps correct deficiency common in CKD and supports bone health before active vitamin D is needed; dosing based on serum 25(OH)D. AJKD

2. Omega-3 fatty acids. May reduce triglycerides and systemic inflammation, supporting cardiovascular risk reduction in CKD diets. Typical supplemental doses 1–2 g/day EPA+DHA. AJKD

3. Oral iron (ferrous sulfate or others). For iron deficiency when IV iron isn’t required; dose split to improve tolerance; monitor ferritin/TSAT. AJKD

4. Folic acid and vitamin B12 (if deficient). Support erythropoiesis in CKD anemia; dose according to deficiency. AJKD

5. Calcium carbonate (dietary binder form). If directed, binds phosphate with meals when non-calcium binders are not used; monitor serum calcium. KDIGO

6. Magnesium (cautious). Corrects low magnesium from binders/diuretics; use carefully in CKD under supervision. KDIGO

7. Fiber (psyllium/inulin). Supports gut health and may help uremic toxin handling; start low to avoid bloating. AJKD

8. Probiotics (adjunct). Evidence is mixed; some regimens aim to lower gut-derived toxins—use only as adjunct. PMC

9. Citrate-rich foods/supplements (as allowed). Adds alkali load that may help metabolic acidosis; must be tailored to potassium status. KDIGO

10. Coenzyme Q10 (optional). Sometimes used for statin-associated muscle symptoms; evidence limited—discuss with clinician. AJKD

---

Immunity / regenerative / stem cell” drugs

There are no FDA-approved regenerative or stem-cell drugs to treat ADTKD or to “repair” kidneys. What does protect you are vaccines that prevent severe infections which can rapidly worsen kidney function. Here are six FDA-approved immunizations commonly recommended for CKD (follow national schedules and clinician advice):

1. Influenza (e.g., Fluzone Quadrivalent; age-specific options). Annual shot to prevent flu complications. U.S. Food and Drug Administration

2. Pneumococcal polysaccharide (PNEUMOVAX 23). Protects against invasive pneumococcal disease; used with conjugate vaccines as advised. U.S. Food and Drug Administration+1

3. Pneumococcal conjugate (e.g., PREVNAR 20 or CAPVAXIVE). Broadened serotype coverage for adults. Pfizer Labeling+1

4. Hepatitis B (e.g., ENGERIX-B; RECOMBIVAX HB including dialysis formulation). Essential before dialysis; protects against HBV. U.S. Food and Drug Administration+1

5. COVID-19 vaccines (follow current national/FDA guidance for CKD). Prevent severe disease and AKI risk; specific labels vary by product and time. KDIGO

6. Other age-appropriate vaccines (e.g., Tdap, zoster) per national schedules for people with CKD. KDIGO

---

Procedures/surgeries

1. Arteriovenous fistula (AVF) creation. A surgeon connects an artery to a vein in the arm to make durable hemodialysis access; best long-term patency when feasible. PMC

2. Arteriovenous graft (AVG). Synthetic tube between artery and vein when veins are unsuitable; matures faster than AVF but needs more interventions. AJKD

3. Peritoneal dialysis catheter placement. Soft tube placed in the abdomen to allow home peritoneal dialysis; preserves residual kidney function in many. AJKD

4. Kidney transplant. Surgical placement of a donor kidney when eGFR is very low or dialysis is needed; ADTKD does not recur in the transplanted kidney. Listing typically begins as eGFR approaches <20 mL/min. KDIGO+1

5. Dialysis access revisions/interventions. Angioplasty/stent-graft or surgical revision to fix stenosis or thrombosis of AV access and keep dialysis reliable. AJKD

---

Preventions

1. Keep BP at guideline targets. KDIGO

2. Limit sodium to <2 g/day; read labels. KDIGO

3. Maintain ~0.8 g/kg/day protein (unless your clinician says otherwise). ScienceDirect

4. Stay vaccinated (flu, pneumococcal, HBV, others). U.S. Food and Drug Administration+2U.S. Food and Drug Administration+2

5. Avoid NSAIDs and other nephrotoxins. KDIGO

6. Treat gout early and consistently. FDA Access Data

7. Don’t smoke; keep active and manage weight. KDIGO

8. Plan dialysis/transplant early as eGFR declines. PMC

9. Review meds at every visit for CKD dosing. KDIGO

10. Educate family and consider genetic testing where appropriate. NCBI

---

When to see doctors (seek timely care)

• New diagnosis of CKD or family history of ADTKD—ask for referral to a nephrologist and consider genetic testing. NCBI

• Rising creatinine/eGFR drop, new edema, uncontrolled BP, or potassium problems—prompt review and medication adjustment. KDIGO

• Gout attacks, especially if frequent or severe—optimize urate-lowering and flare prevention with CKD-safe dosing. FDA Access Data+2FDA Access Data+2

• Anemia symptoms (fatigue, dyspnea)—evaluate iron status and ESA candidacy. FDA Access Data+1

• Advanced CKD (eGFR ~20 or less)—start access planning and transplant evaluation. NIDDK+1

---

What to eat & what to avoid

What to emphasize:

• Fresh, low-sodium foods; cook at home when possible; flavor with herbs/spices instead of salt. NIDDK

• Protein: moderate intake if not on dialysis; adequate/high-quality protein if on dialysis (dietitian-tailored). NIDDK

• Hydration appropriate for your stage and edema status; your team will set limits. NIDDK

What to limit/avoid (based on labs):

• High-potassium foods only if your potassium runs high; avoid potassium-salt substitutes without approval. NIDDK

• High-phosphate processed foods/additives; be cautious with colas and processed meats. FDA Access Data

• Excess protein (if not on dialysis); excess sodium for everyone. NIDDK

---

Frequently Asked Questions (FAQ)

1. Is “medullary cystic kidney disease” the same as ADTKD?
   Yes—ADTKD is the modern name. Many patients don’t have many medullary cysts, so gene-based names are now used. NCBI

2. Which gene is most common?
   MUC1 and UMOD are frequent; REN, HNF1B, SEC61A1 are rarer. NCBI

3. When does kidney failure happen?
   It varies widely (20s–70s). Median age for ADTKD-MUC1 is around the 40s. NCBI

4. Does ADTKD cause lots of protein in urine?
   Usually no; urine is often “bland.” NCBI

5. Why is gout common in some families?
   Because CKD reduces uric acid excretion; UMOD-related disease often has early gout. NCBI

6. Is there a cure?
   No drug cure yet. Transplant is the definitive treatment for kidney failure and ADTKD does not recur in the graft. NCBI

7. Should I get genetic testing?
   If you have compatible features and a family history, it’s reasonable—discuss with a nephrologist/genetics team. NCBI

8. Can blood pressure pills help my kidneys?
   Yes, guideline-directed BP control slows CKD progression. KDIGO

9. What if potassium rises when I take ACEI/ARB?
   Your team may adjust diet, use potassium binders (patiromer or SZC), or modify drugs to keep you safe. FDA Access Data+1

10. How is anemia treated?
    First address iron; ESAs (epoetin alfa or darbepoetin) are used based on hemoglobin targets and risks. FDA Access Data+1

11. Do supplements fix ADTKD?
    No. Some nutrients are adjusted for CKD health under lab guidance, but supplements don’t cure the genetic disease. NIDDK

12. Are stem-cell or “regenerative” shots available?
    No approved stem-cell/regenerative drugs exist for ADTKD. Avoid unproven therapies. NCBI

13. How do dialysis choices differ?
    Hemodialysis filters blood via a machine; peritoneal dialysis uses the abdominal lining at home. Choice depends on lifestyle and medical factors. NIDDK+1

14. Is transplant better than staying on dialysis?
    For most eligible people, transplant offers better survival and quality of life than long-term dialysis. National Kidney Foundation

15. What day-to-day habits help?
    Monitor BP, follow sodium-smart diet, stay hydrated, avoid NSAIDs, keep vaccinations up to date, and see your team regularly. KDIGO+1

Disclaimer: Each person’s journey is unique, treatment plan, life style, food habit, hormonal condition, immune system, chronic disease condition, geological location, weather and previous medical  history is also unique. So always seek the best advice from a qualified medical professional or health care provider before trying any treatments to ensure to find out the best plan for you. This guide is for general information and educational purposes only. Regular check-ups and awareness can help to manage and prevent complications associated with these diseases conditions. If you or someone are suffering from this disease condition bookmark this website or share with someone who might find it useful! Boost your knowledge and stay ahead in your health journey. We always try to ensure that the content is regularly updated to reflect the latest medical research and treatment options. Thank you for giving your valuable time to read the article.

The article is written by Team RxHarun and reviewed by the Rx Editorial Board Members

Last Updated: October 03, 2025.